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Abstract   
Background: Few data exist on the rate of clinical progression for Parkinson’s disease 
(PD) patients who have entered a late stage of the disease.   
Objective: Study the clinical progression of a late-stage PD (LSPD) population over 
one year follow-up. 
Methods: 50 LSPD patients (Schwab and England ADL Scale <50 or Hoehn Yahr 
Stage >3 in MED ON) underwent an extensive clinical assessment at baseline and after 
one year and an acute levodopa test at baseline. 
Results:  Mean age of LSPD patients (female 46%) was 77.5 ± 5.9 years and mean 
disease duration was 15.5± 6.5 years. At baseline, 76% had levodopa-
induced motor complications (MC), usually non-troublesome, 68% were 
demented, 54% had psychosis and 68% depression. Caregiver distress was high. 
L-dopa responsiveness was mild (18% ± 12 of improvement on MDS-UPDRS-
III). After one-year, 20% of the patients were dead, institutionalized or HY 
5. MDS-UPDRS-motor mean score worsened 7.2±10.3 points although there 
was heterogeneity between patients, and there was a global worsening of 
non-motor symptoms, mostly in cognition/mood, urinary nd gastrointestinal 
domains. Nevertheless, MC improved despite similar levodopa equivalent 
dose. Functional independence and quality of life worsened. Dysphagia 
severity at baseline predicted a poor outcome (death, institutionalization or 
HY 5) (Hazard ratio 2.3, 95% CI 1.12- 4.4; p = 0.01), whereas magnitude of L-
dopa response of LSPD patients did not. 
Conclusions: LSPD patients still present a significant, although heterogeneous, motor 
and non-motor progression over 1 year. Dysphagia severity predicts the occurrence of 
















Progression in Parkinson’s disease (PD) seems to be exponential in its later 
stages [1]. Indeed, a number of advanced PD patients enter a later stage 
when motor and non-motor symptoms (NMS) such as falls nd dementia 
rapidly aggravate, causing a major impact on the health status and 
independence of patients [1, 2]. Nonetheless, scarce data exist on the rate of 
clinical progression and prognostic factors for patients who have already entered a late 
disease stage [3, 4]. Equally, uncertainty exists whether the magnitude of levodopa (L-
dopa) responsiveness is a prognostic factor in late-st ge PD (LSPD).  
Our aim was to study the clinical progression and response to L-dopa in a 
LSPD sample over one-year follow-up.  
 
Patients and methods 
Primary objective 
To study the clinical progression of a LSPD population over one year follow-
up.  
Secondary objective 
To study the response of LSPD patients to a suprathreshold dose of L-dopa. 
Study design and patients recruitment 
We performed a cross sectional study and a prospective ohort study. 
Patients were consecutively recruited from the Movement Disorders 















according to the “United Kingdom Parkinson's Diseas Society Brain Bank 
Diagnostic Criteria” (UKBB) criteria [5], were included in the study if they 
had a Schwab and England score (S&E) < 50% [6] or a Hoehn & Yahr  Stage 
(HY) >3 in ”Medication ON” (MED ON). LSPD patients were assessed at 
baseline and at 1 year follow-up (range 12-15 months). The Local Ethical 
Committee approved the study and all patients provided informed consent.   
Patients’ assessment 
At baseline, patients underwent an extensive clinical assessment including a 
challenge test. Details of L-dopa challenge test were previously reported [7, 
8]. Basically, patients have been firstly assessed in “Medication OFF” 
(“MED-OFF”, after 12 hours overnight of anti-dopaminergic drug 
withdrawal) and secondly, in “MED ON” (after the intake of a supramaximal 
dose of L-dopa, 150% of the morning dose). Overall, during both “MED 
OFF” and “MED ON” conditions the following parameters were evaluated: 
a) motor performance using the Movement Disorder Society-Sponsored 
Revision of the Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scale [9],  the 
Modified Abnormal Involuntary Movement Scale (mAIMS)[10]  and the HY 
stage; b) the change of specific NMS: blood pressure (BP) measured in 
supine and 3 minutes after standing, presence of orthostatic hypotension 
(OH), pain and fatigue using a visual analogue scale (VAS-p and VAS-f, 
respectively). L-dopa equivalent daily dose (LEDD) was calculated 
according to standard conversions [11]. Clinical phenotypes, i.e. akinetic-















clinical history. NMS were evaluated using the MDS-UPDRS part I, the 
Non-Motor Symptoms Assessment Scale for PD (NMSS) [12],  the 
Neuropsychiatric Inventory test (NPI) 12-items and the Geriatric Depression 
Scale (GDS) MDS-UPDRS parts II and IV assessed the impact of motor 
symptoms on activities of daily life (ADL) and L-dopa-induced motor 
complications (MCs), respectively. Diagnosis of PD with dementia (PDD) 
was made in agreement with the Level I algorithm of the MDS Task Force 
recommendation for PDD diagnosis [13]. Quality of life (QoL) and health-
related (Hr) QoL were assessed using the PD questionnaire 8 (PDQ-8) 
[14]and the Visual Analogue Scale of the Euro-Qol-5D (EQ-5D VAS). Handicap 
and autonomy in ADL was assessed using the London Ha dicap Scale (LHS) 
[15] and S&E [6],  respectively.  Caregivers’ burden was assessed with the 
Zarit Caregiver Burden Inventory (ZCBI) [16] except in institutionalized 
patients, as a familiar caregiver was absent. At follow-up, patients repeated 
the same clinical assessment with the exception of the ZCBI and the L-dopa 
challenge test. After the L-dopa challenge test andt follow-up, Patients and 
investigator completed the Patient's Global impression-Improvement (PGI-I) 
and the Clinical Global Impression Improvement Scale (CGI-I), respectively.    
Assessments were performed at patients’ home whenever required by 
patients’ health status or caregiver preference. 
 
Statistical Analysis 
Descriptive statistics of demographic, clinical and therapeutic data were 
provided for continuous [mean and standard deviation (SD)] and categorical 















The acute effect of L-dopa was calculated comparing the MDS-UPDRS Part 
III score or sub-items, the mAIMS, BP values, VAS-f, VAS-pain, and OH 
presence/absence in “MED OFF” versus “MED ON”, using the t-test, the 
chi-square test or Fischer’s exact test as appropriate, applying the 
Bonferroni’s correction for multiple comparisons. MDS-UPDRS-III sub-
items for speech (item 3.1), resting tremor (item 3.17), rigidity (item 3.3), 
bradykinesia (sum of items: 3.4-3.8 and 3.14), posture (item 3.13), gait (item 
3.10), freezing of gait (item 3.11), arising from chair (item 3.9), and postural 
instability (item 3.12) were studied separately. Correlations were tested 
using Pearson’s rank correlation coefficient.  
For longitudinal analysis, time-course comparisons of paired data sets were 
performed using Student’s t-test (continuous variables) or chi-square 
(categorical variables) test, as appropriate. Death, being institutionalized de 
novo in a nursing home or progressing to HY 5 at one-year follow-up was 
considered as a combined outcome, whichever occurred first. We have 
performed two Kaplan-Meier survival analysis using two different outcomes; the 
first one explored time to the occurrence of death while the second analysed time 
to the occurrence of the combined outcome of death, institutionalization or HY 5. 
Differences in the estimated survival distribution stratified by presence of 
dementia, psychosis, gender, moderate/severe dysphagia (MDS.UPDRS item 
2.3 >2), and PD phenotype (AK vs. TD) were examined using the log rank 
test. Statistically significant variables (p<0.05) were then used as covariates 
in two Cox-proportional hazard regression models (model 1: dependent 
variable was death; model 2: dependent variable wasthe combined outcome 















significance (0.045<p<0.055), different Cox-proporti nal regression models 
were built and the one which minimized the Akaike information criterion 
[AIC: 2K-2ln (^L), being k be the number of estimated parameters in the model and ^L 
the maximum value of the likelihood function for the model] was selected. The 
following variables were entered in the regression model: age, gender, HY 
(MED OFF), SE (MED OFF), PDD, MDS-UPDRS-item 2.3 (dysphagia severity), 
and NMSS total score.   
All p values reported are two-tailed and a p ≤ 0.05 was considered 
statistically significant. Coefficients and 95% confidence intervals (CIs) are 
reported. SPSS 23.0 statistical software (SPSS, Chicago, IL) was used. 
 
Results 
Demographic and clinical data at baseline 
From an initial sample of 135 HY 4-5 patients, fifty LSPD patients were 
included in the study, in agreement with inclusion/exclusion criteria and 
patients/caregivers‘ availability in participating in the study. Forty patients had 
a S&E < 50% while thirty-eight patients had a HY > 3, and thirty-two fulfilling both 
criteria. Forty-six LSPD patients (92%) were observed at home or nursing 
home due to severe disability. All institutionalized patients lived in nursing homes 
and not in assisted living facilities, as they were mostly dependent in activities of daily 
living and needed medical care and supervision. Indeed LSPD patients presented a 
severe clinical picture with a high prevalence of disability milestones 
(dementia 68%, psychosis 56%, 2 falls per month, wheelchair-bound 18% 
and institutionalization in nursing homes 20%) and NMS (NMSS total score 















HR-QoL and caregiver’s distress (ZBDS score 28.3 ± 13.3) (Table 1). 38 
(76%) of LSPD patients had levodopa-induced MCs, which were troublesome 
only in about a third of the patients (Table 1). Patients with dementia had 
worse scores of MDS-UPDRS-III, NPI-12 items, NMSS, PDQ-8, LHS and 
S&E compared to non-demented LSPD patients (p < 0.05). PDQ-8 
significantly correlated with NMSS and motor impairment (R = 0.74 and R = 
0.54, p <0.01).  
 
LSPD disability progression  
Mortality and combined poor outcome. At one-year follow-up (range 12-15 
months) 10 (20%) LSPD patients were dead (Table 1). All dead patients were 
HY 4-5 at baseline. Kaplan Meier survival curves and the log-rank test 
showed statistical significant difference in the occurrence of the combined 
poor outcome (death, nursing home or progressing HY 5) for 
institutionalized patients at baseline (p = 0.002), patients who needed a 
formal caregiver (p=0.006) and those with moderate/severe dysphagia (MDS-
UPDRS item 2.3 >2) (p = 0.001) (Figure 1 and Supplementary material: 
Table S1). Institutionalized patients, those with moderate/severe dysphagia 
and PDD patients at baseline had a significant poor utcome even when 
considering death as the single final event at follow-up (p=0.01; 0.003; 
0.038, respectively). 
In multivariate Cox-proportional hazard regression analysis, dysphagia 
severity (MDS-UPDRS item 2.3) was the only variable that significantly 
predicted the occurrence of the combined outcome with a hazard ratio of 2.3 















variable that predicted the occurrence of death with a hazard ratio of 2.9 
(1.12- 8.6, 95% CI; p=0.04). Patients with PDD at baseline presented a more 
significant worsening of dysphagia at follow-up if compared to non-
demented patients (p=0.011). 
 
Motor and non-motor progression. Baseline mean MDS-UPDRS motor score 
of patients dead at follow-up was significantly worse compared to that of 
surviving patients, in both ON and OFF state (OFF: 78±12.2 vs 65.5±14.2; 
ON: 69.6±15.6 vs 53.1±14.6, both p =0.02). Four patients withdrew from the 
study (3 did not answer to phone calls and follow-up visits could be not scheduled and 
1 withdrew informed consent). 36 LSPD patients were xamined at one-year 
visit. During follow-up, 7 patients (14%) were hospitalized and 9 (22%) 
were institutionalized. Six cases (16%) changed from HY 2-4 to 5, 
nevertheless median HY stage did not change significantly, though dead 
patients had a significantly higher HY (OFF and ON) at baseline (p<0.05) if 
compared to survivors. Compared to baseline, there was a statistically 
significant worsening of motor and non-motor disability, independence in 
ADL (including a significant worsening in eating tasks abilities, see Table 
1), handicap and HR-QoL. Interestingly, neither thefr quency of fallers nor 
the number of falls\month change significantly at follow-up, but more 
patients were wheelchair-bound (p < 0.001). The mean deterioration of motor 
score (MDS-UPDRS-III, MED ON) (N = 32) was 7.2 (± 10.0) points 
corresponding to a 15.7% (±23.0) increase, with no difference between TD vs AK 
phenotype or patients with/without PDD at baseline. However, 12 patients 















cases (32%) did not deteriorate and, in fact, 10 of these improved between 1-6 
points. The mean progression of MDS-UPDRS part II was significantly 
worse in patients aggravating > 5 points in the motor score compared to 
those worsening ≤ 5 points or improving in the MDS-UPDRS motor score 
(2.1±4.1 vs -1.3±2.9, p = 0.01). The score of MDS-UPDRS part IV 
significantly improved at 1 year follow-up (mean -1.5±3.8 points; 20±50% 
decrease). Fewer patients had motor fluctuations and troublesome motor 
fluctuations, although there were significantly more patients with 
dyskinesias which nevertheless were less troublesome (Table 1). 
The direction of change of NMS between baseline and follow-up differs 
among scales (Table 1). The total score of NMSS worsened significantly 
while MDS-UPDRS Part I and NPI did not. The frequency of PDD was 
similar but MMSE score worsened significantly, as did the scores of the 
items “Cognition” and “Memory” in MDS-UPDRS part I and NMSS, 
respectively. Despite 5 (13%) developing new psychosis, the number of 
patients with psychosis significantly decreased at follow-up although the 
scores of “Hallucinations” item in MDS-UPDRS part I, NMSS and NPI did 
not change. This finding may relate to the fact that 8/10 dead patients had 
baseline psychosis. The total score of GDS was similar between baseline and 
follow-up, although the score of “Depression” item in NPI worsened 
significantly. “Daytime sleepiness” and “Light headedness” (MDS-UPDRS 
part I) were significantly better at follow-up, as was the “Cardiovascular” 
domain of NMSS. The scores of “Urinary” significantly increased at follow-















The score of MDS-UPDRS part II (N = 36) worsened 2.3 points (±4.0) 
corresponding to a 6.0% (±15.0) increase, and S&E scale also significantly 
deteriorated between baseline and follow-up. Handicap (LHS) as well as the 
HR-QoL measured by the EQ-5D-VAS was significantly worse after 1 year, 
although the change in the PDQ-8 was not significant (Table 1).  
 
 
Levodopa acute challenge test  
The mean MDS-UPDRS-III score was 68.1 (±14.1) in MED OFF and 58.4 
(±15.5) in MED ON, with a significant median improvement of 18% (±12) 
(p<0.001) (Table 3). Sub-analysis of MDS-UPDRS-III scores showed a 
significant improvement with L-dopa for appendicular symptoms (rest 
tremor >> rigidity >> bradykinesia) while no significant changes were noted 
for axial signs (Table 3).  
Measurement of BP in orthostatism was not possible in twelve patients 
(24%) (two had symptomatic OH, one an amputee leg and nine a severe 
postural instability). Mean change of SBP from supine to orthostatism as 
well as mean DBP in orthostatism were statistically different between MED 
OFF versus MED ON (Table 3). Four patients developed OH in MED ON, 
which was symptomatic in three (Table 3). 68% of the patients succeeded in 
completing the VAS scales: pain improved significantly after L-dopa intake, 
while fatigue did not (Table 3).  
We found a significant correlation between the ∆mAIMS and the ∆ MDS-
UPDRS-III score (R= 0.64; p<0.0.01). Similarly, MDS-UPDRS-IV total 















strong correlation with the ∆ MDS-UPDRS-III score (R= 0.63 /0.58 
respectively; p<0.001), whereas, though significant, the correlation was 
milder for dyskinesia/motor fluctuations duration sub-items (4.1 and 4.3) 
(R=0.4/0.38 respectively; p<0.05). No significant correlation was found 
between ∆ MDS-UPDRS-III score and ∆VAS-p. Patients with PDD and AK 
phenotype had a poorer motor improvement with L-dopa (p<0.05). No 
correlations were found between ∆ MDS-UPDRS-III score and PDQ-8, EQ-
5D VAS, LHS, S&E and HY. The mean of the PGI-I and CGI-I scales was 3.1 
(±0.9) (“minimally improved”), though 12 patients were not able to answer. 
No serious AEs occurred during the test: eleven cases reported moderate 
drowsiness or fell asleep after L-dopa, three had symptomatic hypotension 




We report the clinical progression of a LSPD cohort ver one-year follow-
up.  After one year, the disease progressed significantly, affecting several 
motor and non-motor domains and about one-fifth of the cases were dead, 
institutionalized or changed to HY 5. Severity of dysphagia at baseline is the 
most important negative prognostic factor for the occurrence of death, 
institutionalization or HY 5.   
As expected, LSPD patients had a high functional dependence, resulting in a 
severe caregiver distress. Indeed, all need a caregiver and one-fifth lived in 
nursing home which is possibly influenced by socio-ultural factors or 















(14%) and US (25%) [17, 18] but lower if compared to the Sydney cohort 
study at 20 years (48%) [4].  
Unexpectedly, we found a high frequency (16%) of HY 2 patients among 
LSPD group, of whom all but one (with severe axial signs) had PDD with 
S&E score < 50%. This reflects a previously described limitation of the HY 
scale, which is heavily weighted toward postural instability [1, 19], and the 
fact that PD patients may become demented before losing balance. Our data 
reinforces the usefulness of the S&E scale to identify the whole spectrum of 
PD patients who entered a late disease stage. LSPD patients had a marked 
impairment in several NMS domains, with a predominance of urinary, 
cognitive and sleep disturbances [2, 20]. Frequency of dementia and 
psychosis is roughly comparable to our previous study [8], while depression 
frequency was lower, even though a fifth of the patien s were not able to fill 
the GDS. This frequency rose 20% if taken into account questionnaires filled 
out with caregivers’ help.  When comparing our result  to the Sydney 
Multicenter study, we find roughly comparable result  for NMS, with a 
similar prevalence of psychosis (50%), depression (50%), urinary 
incontinence (around 70%), equivalent values for MMSE score after 15 years 
of disease (around 22) [21] and frequency of “occasionally choking” (around 
50%), with no patient needing artificial feeding at baseline in both studies. 
Frequency of dementia was higher in the Sydney cohort (83%) [4], probably 
due to different criteria used to diagnose PDD or otherwise because the mean 
duration of PD in our study was shorter.  Over one year, motor and non-
motor scores of LSPD patients worsened significantly. Reported annual 















UPDRS-III within the first five years of disease [22], with a standardized 
annual progression rate of 2.4% in intermediate disease stage [23]. Although 
a slower rate of progression has been reported in more advanced stages of 
PD [23], we found a steeper mean deterioration score at the MDS-UPDRS 
Part III score, highlighting that a faster disease course could take place in 
late disease phase. However, this is not homogenous as a considerable 
percentage of patients deteriorated less than 3 or 5 points, a range that 
includes the minimal clinically important difference value of this scale, 
identified as an increment of 4.68 points , and one-third did not worsen or 
even improved. This heterogeneity might be due to the death of patients in 
poorer motor condition during follow-up or medication adjustment after L-
dopa test or, alternatively, may suggest that only a sub-group of LSPD 
patients rapidly evolves while stabilization or even improvement of 
symptoms is still possible. A faster progression of midline motor disability 
could explain the higher motor score deterioration f und in our study [25]. 
The low rate of patients lost at follow-up (8%) and their similar baseline scores if 
compared to the other patients, would unlikely had an impact on our higher motor score 
progression. Annual progression rate of 2.2 points in UPDRS-II has been 
reported [23] for intermediate stage PD patients, which is similar to our 
findings. Interestingly, L-dopa induced MCs significantly decreased at 
follow-up despite similar LEDD, confirming the low frequency of 
troublesome MCs among LSPD [2, 7].   
Among NMS, cognition/mood, urinary and gastrointestinal dysfunction 
progressed the most. Cardiovascular symptoms seem to decrease. A possible 















due to cognitive impairment, the fact that BP measurement was not possible 
in 24% of the cases, the fact that dead patients had a higher though not 
significant score for cardiovascular symptoms at baseline or because patients 
spend more time supine. 
Institutionalized patients and those with more sever  dysphagia have a 
higher risk of death, institutionalization or HY 5 within one year. Nursing 
home residents with PD may have a 30% higher mortality rate compared to 
community dwelling patients [26]. In many instances, those patients are 
under-treated for motor symptoms, although interventions could lead to 
significant improvements in functioning and QoL [20, 27]. LSPD patients in 
nursing homes are a fragile subgroup, whose treatmen  is particularly 
challenging, as expertise in the management of PD is not uniform among 
healthcare professionals of nursing homes. In multivariate analysis, only 
dysphagia severity predicts a poor outcome. Interestingly, despite a 28% 
frequency of severe dysphagia, only one patient had a gastrostomy. 
Nonetheless, the main confirmed death cause was pneumonia and one patient 
died due to food asphyxiation. As frequent pulmonary infections is the 
leading cause of death in PD [28, 29], our results s ress the relevance of 
swallowing monitoring in LSPD patients. Of note, none of our patients had 
the chance to do swallowing therapy or aspiration pneumonia prevention 
strategies (data not shown), due to their difficulties in reaching a swallowing 
therapy centre.  
Of note, the magnitude of acute L-dopa response does not predict 
progression of PD at this disease stage. This may be accounted for a floor 















below a certain level, its impact on patients’ global functioning and disease 
progression is minimal. In this study, the magnitude of L-dopa 
responsiveness in LSPD was slightly higher compared to our previous 
findings (18% vs 11%; 12.7 vs 8.5 points) [7]. This difference could be 
attributed to a larger sample or the inclusion of a larger spectrum of LSPD 
patients (namely HY 2 cases), even if other clinical features are alike. The 
clinical significance of this better motor response i  marginal according to 
the CGI-I/PGI-I and the change in the S&E between off and on state. Our 
results corroborate the unresponsiveness of axial signs to L-dopa in late 
stage. L-dopa response in LSPD patients was correlated with dyskinesias, 
adding evidence to our previous suggestion of cautiously increasing L-dopa 
dose in those patients manifesting MCs or in whom tremor or rigidity are the 
most troublesome signs [7]. LSPD patients with AK phenotype or PDD had a 
worse response to L-dopa, which is contrary to previous findings [25, 30]. 
However, the adoption of different definitions for cognitive impairment and 
TD phenotype may explain the divergent results [25].  
 
The strength of our study is to couple data on L-dopa responsiveness with an 
extensive and longitudinal description of clinical features [3] in a cohort of 
LSPD patients, who are rarely included in clinical studies. For the first time, 
we show that dysphagia predicts a worse outcome in these patients and some 
may still benefit from an increase in L-dopa [30, 31].    
Unblinded clinical assessment is the main limitation f our study. However, 
our results are in line with ours [7, 8] and others’ previous reports,[3, 4, 20, 















tempered by a possible underestimation of other factors of poor prognosis, 
due to the application of a multivariate analysis to a small sample of 
patients. Finally, there is a limitation regarding dysphagia assessment. Our 
study was not specifically designed to assess swallowing problems among 
LSPD patients, but to investigate overall clinical progression of these 
patients. For this reason, we investigated dysphagia by means of a subjective 
measure, i.e. the MDS-UPRDS, commonly used in clinial practice even if it 
can underestimate the problem [32] and we did not clle t specific 
information on patients’ diet and oral hygiene status. However, alternative 
objective and  instrumental assessments of swallowing, such as fibre optic 
endoscopic evaluation of swallowing or videofluroscpy, require patients’ 
collaboration and are in-hospital procedures [33, 34], which was not 
applicable during in-home visits of demented and frail patients. Taken as a 
whole this highlights the possible underestimation of swallowing 
dysfunctions among our LSPD population and the need to perform dysphagia 
and nutrition-focused objective assessments among in LSPD.  
 
Conclusion 
LSPD is an orphan population expected to increase in the near future and 
responsible for a high caregiver burden. Their motor and non-motor 
disability is severe, and 20% is institutionalized. Nevertheless, clinical 
heterogeneity exists and the severity of axial sign and cognitive decline 
varies considerably. Consequently, even if disability milestones usually 
progress exponentially, a slower decline may also be possible. One-fifth dies 















predicts a worse outcome, and attention should thus be taken to careful 
assessment and management of swallowing problems. On the other hand, L-
dopa responsiveness seems to have no impact on prognosis in this late stage, 
although L-dopa maintains a slight effect on appendicular signs and 
especially in those cases with MCs, in whom the dose might be cautiously 
increased. Nevertheless, higher L-dopa dose will not improve swallowing 
and non-pharmacological interventions must be prioritized. Future 
pharmacological and non-pharmacological studies on LSPD patients should 
be mostly oriented to the management of dysphagia and other L-dopa 

















The authors thank all the patients and their families for participating in this study. 
 
Funding source: The study had no specific funding. 
 
Authors’ Contributions 
1. Research project: A. Conception, B. Organization, C. Execution; 2. Statistical 
Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: 
A. Writing of the first draft, B. Review and Critique.  
Dr. Margherita Fabbri: 1A, 1C, 2A, 3A; 
Prof. Miguel Coelho: 1A, 1B, 2C, 3B; 
Daisy Abreu: 1B, 2A, 2B; 
Prof. Catarina Godinho: 1C; 2B; 3B;  
Rita Cardoso: 1C; 2 A; 3B;  
Prof. Isabel Guimaraes: 1C; 2 A; 3B; 
Dr. Leonor C Guedes: 1B, 3B;  
Dr. Mario M. Rosa: 1B, 3B; 
Dr. Maurizio Zibetti: 1A, 3B; 
Prof. Leonardo Lopiano: 1A, 3B; 
Prof. Angelo Antonini: 1A, 2C, 3B; 
Prof. Joaquim J Ferreira: 1A, 1B, 3B; 
Conflict of interest and Financial Disclosures 
Dr. Margherita Fabbri: no conflict of interest to report. Stock Ownership in medically-
related fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; 















Testimony: none; Employment: Phd student, Instituto de Medicina Molecular, Lisbon; 
Contracts: none; Royalties: none; Other: none. 
Prof. Miguel Coelho: no conflict of interest to report. Stock Ownership in medically-
related fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; 
Honoraria to speak: none; Grants: none; Intellectual Property Rights: none; Expert 
Testimony: none; Employment: Neurologist at the Department of Neurosciences, 
Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, 
Lisboa, Portugal; Contracts: none; Royalties: none; Other: none. 
Daisy Abreu: no conflict of interest to report. Stock Ownership in medically-related 
fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; Honoraria 
to speak: none; Grants: none; Intellectual Property Rights: none; Expert Testimony: 
none; Employment: statistician at Clinical Pharmacology Unit, Instituto de Medicina 
Molecular, Lisbon; Contracts: none; Royalties: none; Other: none. 
Prof. Catarina Godinho: no conflict of interest to report. Stock Ownership in medically-
related fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; 
Honoraria to speak: none; Grants: none; Intellectual Property Rights: none; Expert 
Testimony: none; Employment: Instituto Universitário Egas Moniz; Contracts: none; 
Royalties: none; Other: none. 
Rita Cardoso: no conflict of interest to report. Stock Ownership in medically-related 
fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; Honoraria 
to speak: none; Grants: none; Intellectual Property Rights: none; Expert Testimony: 
none; Employment: Speech and Language Therapist at Campus Neurológico Sénior, 
Torres Vedras; Contracts: none; Royalties: none; Other: none. 
Prof. Isabel Guimaraes: no conflict of interest to report. Stock Ownership in medically-















Honoraria to speak: none; Grants: none; Intellectual Property Rights: none; Expert 
Testimony: none; Employment: speech and language therapist at Escola Superior de 
Saúde de Alcoitão; Contracts: none; Royalties: none; Other: none. 
Prof. Leonor Guedes: no conflict of interest to report. Stock Ownership in medically-
related fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; 
Honoraria to speak: none; Grants: none; Intellectual Property Rights: none; Expert 
Testimony: none; Employment: Neurologist at the Department of Neurosciences, 
Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, 
Lisboa, Portugal; Contracts: none; Royalties: none; Other: none. 
Dr. Mario M. Rosa: no conflict of interest to report. Stock Ownership in medically-
related fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; 
Honoraria to speak: none; Grants: none; Intellectual Property Rights: none; Expert 
Testimony: none; Employment: Neurologist at the Department of Neurosciences, 
Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, 
Lisboa, Portugal and member of the Scientific Advaice working party at EMA since 
2011; Contracts: none; Royalties: none; Other: none. 
Dr. Maurizio Zibetti no conflict of interest to report. Stock Ownership in medically-
related fields: none; Honoraria to speak and grants: Medtronic, Lundbeck, UCB Pharma 
and AbbVie; Advisory Boards: none; Partnership: none; I tellectual Property Rights: 
none; Expert Testimony: none; Employment: Neurologist at A.O.U Città della Salute e 
della Scienza, Torino; Contracts: none; Royalties: none; Other: none.  
Prof. Leonardo Lopiano no conflict of interest to report. Stock Ownership in medically-
related fields: none; Honoraria to speak and grants: Medtronic, UCB Pharma, AbbVie 















Rights: none; Expert Testimony: none; Employment: Neurologist at the Department of 
Neuroscience, University of Turin; Contracts: none; Royalties: none; Other: none.  
 
Prof. Angelo Antonini: no conflict of interest to report. Stock Ownership in medically-
related fields: none; Consultancies: UCB, Boston Scientific, AbbVie, Zambon. 
Advisory Boards: Boston Scientific, AbbVie, Zambon. Honoraria to speak: AbbVie, 
Zambon, Lundbeck. Grants: Mundipharma, Neureca Foundation, the Italian Ministry 
Research Grant N RF-2009-1530177 and Horizon 2020 Program Grant N: 643706; 
Intellectual Property Rights: none; Expert Testimony: Served as Boehringer Ingelheim 
expert testimony on legal cases for pathological gambling  
Prof. Joaquim J. Ferreira: no conflict of interest to report. Stock Ownership in 
medically-related fields: none; Consultancies: Ipsen, GlaxoSmithKline, Novartis, Teva, 
Lundbeck, Solvay, Abbott, BIAL, Merck-Serono and Merz; Advisory Boards: none; 
Partnership: none; Honoraria to speak: none; Grants: GlaxoSmithKline, Grunenthal, 
Teva and Fundação MSD; Intellectual Property Rights: none; Expert Testimony: none; 
Employment: Laboratory of Clinical Pharmacology and Therapeutics of Lisbon; 



















[1] M. Coelho, J.J. Ferreira, Late-stage Parkinson disease, Nature reviews. Neurology 
8(8) (2012) 435-42. 
[2] M. Coelho, M.J. Marti, E. Tolosa, J.J. Ferreira, F. Valldeoriola, M. Rosa, C. 
Sampaio, Late-stage Parkinson's disease: the Barcelona and Lisbon cohort, Journal of 
neurology 257(9) (2010) 1524-32. 
[3] R. Cilia, E. Cereda, C. Klersy, M. Canesi, A.L. Zecchinelli, C.B. Mariani, S. Tesei, 
G. Sacilotto, N. Meucci, M. Zini, C. Ruffmann, I.U. Isaias, S. Goldwurm, G. Pezzoli, 
Parkinson's disease beyond 20 years, Journal of neurology, neurosurgery, and 
psychiatry 86(8) (2015) 849-55. 
[4] M.A. Hely, M.A. Reid Wg Fau - Adena, G.M. Adena Ma Fau - Halliday, J.G.L. 
Halliday Gm Fau - Morris, J.G. Morris, The Sydney multicenter study of Parkinson's 
disease: the inevitability of dementia at 20 years, 2008 (1531-8257 (Electronic)) (2008). 
[5] A.J. Hughes, S.E. Daniel, L. Kilford, A.J. Lees, Accuracy of clinical diagnosis of 
idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, Journal of 
neurology, neurosurgery, and psychiatry 55(3) (1992) 181-4. 
[6] R.S. Schwab, A. England, Projection technique for evaluating surgery in 
Parkinson’s disease in 3rd Symposium on Parkinson’s Disease, eds Gillingham, F. J. & 
Donaldson, M. C.  (1969) 152-157. 
[7] M. Fabbri, M. Coelho, D. Abreu, L.C. Guedes, M.M. Rosa, N. Costa, A. Antonini, 
J.J. Ferreira, Do patients with late-stage Parkinson's disease still respond to levodopa?, 
Parkinsonism & related disorders 26 (2016) 10-6. 
[8] M. Fabbri, M. Coelho, L.C. Guedes, I. Chendo, C. Sousa, M.M. Rosa, D. Abreu, N. 
Costa, C. Godinho, A. Antonini, J.J. Ferreira, Response of non-motor symptoms to 
levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test, 
Parkinsonism & related disorders 39 (2017) 37-43. 
[9] C.G. Goetz, S. Fahn, P. Martinez-Martin, W. Poewe, C. Sampaio, G.T. Stebbins, 
M.B. Stern, B.C. Tilley, R. Dodel, B. Dubois, R. Holloway, J. Jankovic, J. Kulisevsky, 
A.E. Lang, A. Lees, S. Leurgans, P.A. LeWitt, D. Nyenhuis, C.W. Olanow, O. Rascol, 
A. Schrag, J.A. Teresi, J.J. Van Hilten, N. LaPelle, Movement Disorder Society-
sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): 
Process, format, and clinimetric testing plan, Movement disorders : official journal of 
the Movement Disorder Society 22(1) (2007) 41-7. 
[10] M.R. Munetz, S. Benjamin, How to examine patients using the Abnormal 
Involuntary Movement Scale, Hospital & community psychiatry 39(11) (1988) 1172-7. 
[11] C.L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, C.E. Clarke, Systematic 
review of levodopa dose equivalency reporting in Parkinson's disease, Movement 
disorders : official journal of the Movement Disorde  Society 25(15) (2010) 2649-53. 
[12] K.R. Chaudhuri, P. Martinez-Martin, R.G. Brown, K. Sethi, F. Stocchi, P. Odin, 
W. Ondo, K. Abe, G. Macphee, D. Macmahon, P. Barone, M. Rabey, A. Forbes, K. 
Breen, S. Tluk, Y. Naidu, W. Olanow, A.J. Williams, S. Thomas, D. Rye, Y. Tsuboi, A. 
Hand, A.H. Schapira, The metric properties of a novel non-motor symptoms scale for 
Parkinson's disease: Results from an international pilot study, Movement disorders : 
official journal of the Movement Disorder Society 22(13) (2007) 1901-11. 
[13] B. Dubois, D. Burn, C. Goetz, D. Aarsland, R.G. Brown, G.A. Broe, D. Dickson, 
C. Duyckaerts, J. Cummings, S. Gauthier, A. Korczyn, A. Lees, R. Levy, I. Litvan, Y. 
Mizuno, I.G. McKeith, C.W. Olanow, W. Poewe, C. Sampaio, E. Tolosa, M. Emre, 















movement disorder society task force, Movement disor ers : official journal of the 
Movement Disorder Society 22(16) (2007) 2314-24. 
[14] C. Jenkinson, R. Fitzpatrick, Cross-cultural evaluation of the short form 8-item 
Parkinson's Disease Questionnaire (PDQ-8): results from America, Canada, Japan, Italy 
and Spain, Parkinsonism & related disorders 13(1) (2007) 22-8. 
[15] C.A. Perenboom RJ, Measuring participation according to the International 
Classification of Functioning, Disability and Health (ICF), Disabil Rehabil 25 (2003) 
577-587. 
[16] S.H. Zarit, K.E. Reever, J. Bach-Peterson, Relatives of the impaired elderly: 
correlates of feelings of burden, The Gerontologist 20(6) (1980) 649-55. 
[17] A. Hand, W.K. Gray, L.L. Oates, M. Woolford, A. Todd, E. Bale, C. Jones, B.H. 
Wood, R.W. Walker, Medication use in people with late stage Parkinson's disease and 
parkinsonism living at home and in institutional care in north-east England: A balance 
of symptoms and side-effects?, Parkinsonism & related disorders 32 (2016) 120-123. 
[18] D. Safarpour, D.P. Thibault, C.L. DeSanto, C.M. Boyd, E.R. Dorsey, B.A. Racette, 
A.W. Willis, Nursing home and end-of-life care in Parkinson disease, Neurology 85(5) 
(2015) 413-9. 
[19] C.G. Goetz, W. Poewe, O. Rascol, C. Sampaio, G.T. Stebbins, C. Counsell, N. 
Giladi, R.G. Holloway, C.G. Moore, G.K. Wenning, M.D. Yahr, L. Seidl, Movement 
Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and 
recommendations, Movement disorders : official journal of the Movement Disorder 
Society 19(9) (2004) 1020-8. 
[20] N.J. Weerkamp, S.U. Zuidema, G. Tissingh, P.J.oels, M. Munneke, R.T. 
Koopmans, B.R. Bloem, Motor profile and drug treatment of nursing home residents 
with Parkinson's disease, Journal of the American Geriatrics Society 60(12) (2012) 
2277-82. 
[21] M.A. Hely, W.G.J. Morris Jg Fau - Reid, R. Reid Wg Fau - Trafficante, R. 
Trafficante, Sydney Multicenter Study of Parkinson' disease: non-L-dopa-responsive 
problems dominate at 15 years, (0885-3185 (Print)) (2005). 
[22] D.C. Velseboer, M. Broeders, B. Post, N. van Geloven, J.D. Speelman, B. 
Schmand, R.J. de Haan, R.M. de Bie, Prognostic factors of motor impairment, 
disability, and quality of life in newly diagnosed PD, Neurology 80(7) (2013) 627-33. 
[23] A. Schrag, R. Dodel, A. Spottke, B. Bornschein, U. Siebert, N.P. Quinn, Rate of 
clinical progression in Parkinson's disease. A prosective study, Movement disorders : 
official journal of the Movement Disorder Society 22(7) (2007) 938-45. 
[24] K. Horvath, Z. Aschermann, P. Acs, G. Deli, J. Janszky, S. Komoly, E. Balazs, K. 
Takacs, K. Karadi, N. Kovacs, Minimal clinically important difference on the Motor 
Examination part of MDS-UPDRS, Parkinsonism & relatd disorders 21(12) (2015) 
1421-6. 
[25] G. Ganga, J.E. Alty, B.G. Clissold, C.D. McColl, K.A. Reardon, M. Schiff, P.A. 
Kempster, Longitudinal study of levodopa in Parkinso '  disease: effects of the 
advanced disease phase, Movement disorders : official journal of the Movement 
Disorder Society 28(4) (2013) 476-81. 
[26] C.G. Goetz, G.T. Stebbins, Mortality and hallucinations in nursing home patients 
with advanced Parkinson's disease, Neurology 45(4) (1995) 669-71. 
[27] M. Makoutonina, R. Iansek, P. Simpson, Optimizing care of residents with 
















[28] B. Pinter, A. Diem-Zangerl, G.K. Wenning, C. Scherfler, W. Oberaigner, K. Seppi, 
W. Poewe, Mortality in Parkinson's disease: a 38-year follow-up study, Movement 
disorders : official journal of the Movement Disorde  Society 30(2) (2015) 266-9. 
[29] S. Pennington, K. Snell, M. Lee, R. Walker, The cause of death in idiopathic 
Parkinson's disease, Parkinsonism & related disorders 16(7) (2010) 434-7. 
[30] C. Ding, G. Ganesvaran, J.E. Alty, B.G. Clissold, C.D. McColl, K.A. Reardon, M. 
Schiff, V. Srikanth, P.A. Kempster, Study of levodopa response in Parkinson's disease: 
Observations on rates of motor progression, Movement disorders : official journal of the 
Movement Disorder Society 31(4) (2016) 589-92. 
[31] S.-D.F. Schade S, Ebentheuer J, Schulz X, Trenkwalder C, Mollenhauer B, Acute 
Levodopa Challenge Test in Patients with de novo Parkinson’s Disease: Data from the 
DeNoPa Cohort, Movement Disorder and Clinical practice  (2017). 
[32] J.G. Kalf, B.J. de Swart, B.R. Bloem, M. Munneke, Prevalence of oropharyngeal 
dysphagia in Parkinson's disease: a meta-analysis, Parkinsonism & related disorders 
18(4) (2012) 311-5. 
[33] T. Warnecke, I. Suttrup, J.B. Schroder, N. Osada, S. Oelenberg, C. Hamacher, S. 
Suntrup, R. Dziewas, Levodopa responsiveness of dysphagia in advanced Parkinson's 
disease and reliability testing of the FEES-Levodopa-test, Parkinsonism & related 
disorders 28 (2016) 100-6. 
[34] d.S.B. Kalf JG, Bonnier M, Hofman M, Kanters J, Kocken J, Miltenburg M, Bloem 
BR, Munneke M, Guidelines for speech-language therapy in Parkinson’s disease., The 

















LEGEND FOR FIGURE 
Figure 1. Kaplan-meier curves for the occurrence of the combined poor outcome 
(death/be institutionalized/HY 5) at follow-up for patients who are institutionalized (A), 




LEGEND FOR TABLES 
Table 1. Values are presented as mean (SD) if no otherwise specified. HY: Hoehn Yahr  
Stage; S&E: Schwab and England score; GDS: Geriatric Depression Scale (mild 
depression: 11- 20; severe depression: 21- 30); LEDD: levodopa equivalent daily dose; 
PDD: Parkinson’s disease with dementia; BMI: Body max index; MMSE: Mini Mental 
State Examination; EQ-5D VAS: Visual Analogue Scale of the Euro-Qol-5D; PDQ-8: 
PD questionnaire-8;NPI-12: Neuropsychiatric Inventory test 12-items; ZCBI: Zarit 
Caregiver Burden Inventory; LHS: London Handicap Scale; NMSS: Non motor 
symptoms scale; DDS: dopamine dysregulation syndrome; PEG: percutaneous 
endoscopic gastrostomy; Missing data: (*) → GDS 11/50 (22%) at baseline and 11/36 
(30%) at follow-up; ED-5D VAS: 14/50 (28%) at baselin  and 2/36 (5%) at follow-up; 
^ Caregiver definition: 0= informal at home; 1= formal at home; nurses= 2; 3= not 
necessary/present; **This significance refers to the progression of MDS-UPDRS – I 
score of those patients assessed with MDS-UPDRS- I at follow-up (N = 36); the score 
worsened 0.7 points (±4.0) corresponding to a 8.0% (±24.3) increase. *** This 
significance refers to the progression of MDS-UPDRS – II score of those patients 
assessed with MDS-UPDRS- II at follow-up (N = 36); the score worsened 2.3 points 















progression of MDS-UPDRS – IV score of those patients assessed with MDS-UPDRS- 
IV at follow-up (N = 36); the score improved  -1.5 points (±3.8) corresponding to a 20% 
(±54.8) increase.***** This significance refers to he progression of MDS-UPDRS – III 
MED ON score of those patients assessed with MDS-UPDRS- III at follow-up (N = 
32); the score worsened 7.2 points (±10.0) corresponding to a 15.7% (±23.0) increase. 
NA: not available; ns: not significant. At MDS-UPDRS-I, NPI 12 item and NMSS a 
patient was considered as having a “positive” score f r the item if score was ≥1; P 
values for baseline vs. follow-up questionnaires, and for ADPD vs. LSPD scores refer 
to mean values and not to number of affected patients.  
Table 2. Multivariable Cox Proportional Hazards Model for time to death/be 
institutionalized/HY 5. HY: Hoehn Yahr Stage; S&E: Schwab and England score; 
PDD: Parkinson’s disease with dementia. AK: akinetic-rigid; NMSS: Non motor 
symptoms scale. 
Table 3. L-dopa challenge test. Values are presented as mean (SD) if no otherwise 
specified. VAS-p: visual analogue scale for pain; VAS-f: visual analogue scale for 
fatigue; HY: Hoehn Yahr  Stage; S&E: Schwab and Engla d score; BP_supine: blood 
pressure in supine position: BP_orto: blood pressure after 3 minutes of standing; 1-OT: 
orthostatic hypotension; 1-OH: defined as decrease in ystolic pressure >30 mmHg and 
in diastolic pressure>15 mmHg, within 3 minutes of tanding; 2-OH: defines as  
decrease in systolic pressure >20 mmHg and in diastol c pressure>10 mmHg, within 3 
minutes of standing. Missing data: (*) VAS-p and VAS-f 16/50; BP: 12/50; 
Supplementary material 
Table S1. Log-rank P values for time to “combined outcome” (death/be 
institutionalized/HY 5). PDD: Parkinson’s disease with dementia; AK: akinetic-rigid; 


































1 year follow-up 
 
Baseline vs. 1 
year follow-up  
Age (yrs) 77.5 (5.9) 77.8 (7.2) / 
Education (yrs) 6 (5) / / 
Women (n/total (%)) 23/50 (46%) 17/36 (47%) ns 
BMI (Kg/m2) 22.8 (3.4) 22.3 (3.5) <0.001 
Age at disease onset (yrs) 62 (9.5) / / 
Disease duration (yrs) 15.5 (6.5) 17 (6) / 
Levodopa treatment duration (yrs) 11.5 (8.9) / / 
LEDD 1046 (388) 1033 (354) ns 
S&E (ON/OFF) 35.8 (12) / 30 (12) 28.6 (15.1)/NA <0.001 
HY (ON/OFF) 3.8 (0.9) / 4 (1) 3.7 (1.1) /NA ns 
LHS 0.3 (0.11) 0.28 (0.11) <0.001 























PDD (n (%)) 34 (68%) 22 (61%) ns 
MMSE 21.4 (5) 19.7 (7.9) <0.05 
Psychosis (n (%)) 







Urinary incontinence - % 







































 Nursing home 10 (20%) 8 (22%) <0.05 
Eating tasks independency 
MDS-UPDRS 2.4 
MDS-UPDRS 2.3 ≥2 - % 
Dysphagia severity 
MDS-UPDRS 2.3  
MDS-UPDRS 2.3 = 0- n, % 
MDS-UPDRS 2.3 = 1- n, % 
MDS-UPDRS 2.3 = 2 -  n, % 
MDS-UPDRS 2.3 = 3 – n, % 
MDS-UPDRS 2.3 = 4 – n, % 
MDS-UPDRS 2.3 ≥2 – n,  % 
MDS-UPDRS ≥3 - n, % 
 








9 – 18% 
12 – 24% 
18 – 36% 
11 – 22% 
0 
54% 









9 – 25% 
7 – 19% 
14 – 38% 
6 – 16% 
2- 5% 
61% 








              
              ns 
 
 
Caregiver  ̂ 0 = 27 (54%) 
1= 13 (26%) 
2= 10 (10%) 
0= 21 (58%) 
1= 6 (16%) 
2= 9 (25%) 
ns 
ZBDS 28.3 (13.3) NA / 




pneumonia (n = 4); not 
determined (n = 4); 
intestinal cancer (n = 
1); food asphyxiation 


































MDS-UPDRS-I, total score  
Score, mean (SD) - nº of patients scoring positive 
























2.9 (1.2) – 92% 
1.4 (1.4) – 54 % 
1.9 (0.9) – 88% 
1.5 (1.2) – 72% 
1.8 (1.4) - 70% 
0.2 (0.5) – 16% 
1.4 (1.2) – 68% 
1.6 (0.8) – 86% 
1.6 (1.2) - 74% 
2.3 (1.1) – 94% 
1.7 (1.3)- 74% 
1.2 (0.9) – 68% 










3.1 (1.5) – 94% 
1.3 (1.4) – 50% 
2.2 (0.9) – 97% 
1.8 (0.9) – 91% 
1.9 (1.4) – 80% 
0.2 (1.4) – 2% 
1.3 (1.2) – 77% 
1.1 (0.8) – 80% 
1.8 (1.1) – 86% 
2.9 (1.1) – 94% 
1.8 (1.1) – 83% 
0.7 (0.9) – 44% 




























L-dopa induced Motor complications (n (%)) 
Motor fluctuations (n (%)) 
Troublesome motor fluctuations (n (%)) 
Dyskinesias (n (%)) 
Troublesome Dyskinesias (n (%)) 
















<0.01   
<0.01  
ns 
PDQ-8 60.4 (15) 62.1 (17.2) ns 
EQ-5D-VAS 43.7 (14.3) * 39.7 (15)* <0.01 
NMSS total score 
Score, mean (SD) - nº of patients scoring positive 












2.7 (3.4) – 61% 
12.5 (7.2) – 100% 
20.5 (7.2) - 96% 
6.5 (8.2) – 58% 
20 (12.5) – 98% 





1.3 (1.7) - 47% 
10 (7.5) – 100% 
24.2 (18.4) – 97% 
6.6 (8.6) – 52% 
22.1 (10.7) – 100% 






































Table 1. Demographic and clinical characteristics of LSPD patients. Values are presented as mean (SD) if no otherwise specified. HY: Hoehn Yahr  Stage; 
S&E: Schwab and England score; GDS: Geriatric Depression Scale (mild depression: 11- 20; severe depression: 21- 30); LEDD: levodopa equivalent daily dose; 
PDD: Parkinson’s disease with dementia; BMI: Body max index; MMSE: Mini Mental State Examination; EQ-5D VAS: Visual Analogue Scale of the Euro-Qol-
5D; PDQ-8: PD questionnaire-8;NPI-12: Neuropsychiatric Inventory test 12-items; ZCBI: Zarit Caregiver Burden Inventory; LHS: London Handicap Scale; 
NMSS: Non motor symptoms scale; PEG: percutaneous endoscopic gastrostomy; DDS: dopamine dysregulation syndrome; Missing data: (*) → GDS 11/50 
(22%) at baseline and 11/36 (30%) at follow-up; ED-5  VAS: 14/50 (28%) at baseline and 2/36 (5%) at follow-up; ^ Caregiver definition: 0= informal at home; 
1= formal at home; nurses= 2; 3= not necessary/present; **This significance refers to the progression of MDS-UPDRS – I score of those patients assessed with 
MDS-UPDRS- I at follow-up (N = 36); the score worsened 0.7 points (±4.0) corresponding to a 8.0% (±24.3) increase. *** This significance refers to the 
progression of MDS-UPDRS – II score of those patients assessed with MDS-UPDRS- II at follow-up (N = 36); the score worsened 2.3 points (±4.0) 




17 (11.3) -94% 
20 (6.3) - 100% 
9.6 (5.4) 100% 
20.5 (12.9) – 97% 
23.3 (1.9) – 100% 




NPI-12 total score 
 Score, mean (SD) - nº of patients scoring positive 











Motor aberrant behaviour 
Sleep and Nighttime Behavior Disorders 





1.3 (2.2) – 28% 
2.5 (3.4) -52% 
1.9 (3) – 48% 
3 (1.9) – 88% 
2.5 (2.5) – 68% 
0.1 (0.6) – 6% 
3.7 (3.7) – 70 % 
0.08 (0.3) – 6% 
1.4 (2.3) – 52% 
1.7 (3) – 39% 
4 (3.3) – 92% 





1.5 (2.4) – 42% 
2.8 (3.8) – 50% 
1.5 (1.9) – 50% 
4.7 (3.1) – 97% 
3.4 (2.3) – 88% 
0.3 (2.1) – 5% 
3.9 (4) – 72% 
0.1 (0.7) – 2% 
1.5 (1.9) – 50% 
2.2 (3.7) – 38% 
2.4 (3.1) – 92% 





























UPDRS- IV at follow-up (N = 36); the score improved  -1.5 points (±3.8) corresponding to a 20% (±54.8) increase.***** This significance refers to the 
progression of MDS-UPDRS – III MED ON score of those patients assessed with MDS-UPDRS- III at follow-up (N = 32); the score worsened 7.2 points (±10.0) 
corresponding to a 15.7% (±23.0) increase. NA: not available; ns: not significant. At MDS-UPDRS-I, NPI 12 item and NMSS a patient was considered as having 






















Table 2. Multivariable Cox Proportional Hazards Model for time to death/be 
institutionalized/HY 5.  
HY: Hoehn Yahr Stage; S&E: Schwab and England score; PDD: Parkinson’s disease 
with dementia. AK: akinetic-rigid; NMSS: Non motor symptoms scale.  
Variable Hazard Ratio (95% CI)  P - value 
Age 1.02 (0.93-1.11) 0.66 
Gender 0.56 (0.18-1.73) 0.32 
S&E (MED OFF) 0.95 (0.89 – 1.02) 0.21 
HY (MED OFF) 0.91 (0.42- 1.95) 0.81 
PDD 1.38 ( 0.23- 7.99) 0.71 
NMSS total score 0.99 (0.99- 1.01) 0.59 
MDS-UPDRS-item 2.3 
(dysphagia) 































































Table 3. L-dopa challenge test. Values are presented as mean (SD) if no otherwise specified. VAS-p: visual 
analogue scale for pain; VAS-f: visual analogue scale for fatigue; HY: Hoehn Yahr  Stage; S&E: Schwab and 
England score; BP_supine: blood pressure in clinostatic position: BP_orto: blood pressure after 3 minutes of 
standing; 1-OT: orthostatic hypotension; 1-OH: defined as decrease in systolic pressure >30 mmHg and in 
diastolic pressure>15 mmHg, within 3 minutes of standing; 2-OH: defines as  decrease in systolic pressure >20 
mmHg and in diastolic pressure>10 mmHg, within 3 minutes of standing. Missing data: (*) VAS-p and VAS-f 
16/50; BP: 12/50; 
 
 
LSPD patients (N= 50) 
 MED OFF MED ON p - value 
 
MDS-UPDRS-III 
68.1 (14.1) 58.4 (15.5) < 0.001 
 
Speech 
2.5 (1.1) 2.5 (1.1) 0.1 
 
Rigidity 
9.7 (5) 6.5  (5) < 0.001 
 
Bradykinesia 
34.5 (6) 31.5 (6) < 0.001 
 
Rest tremor 
2,1 (2.8) 0.6 (1.3) < 0.001 
 
Arising from chair 
3.3 (0.9) 3 (1) 0.001 
 
Freezing of gait 
2.6 (1.3) 2.4 (1.3) 0.05  
 
Postural Stability 
3 (0.9) 2.9 (0.9) 0.05 
Posture 2.3 (0.8) 2.2 (0.8) 0.3 
 
Gait 
3.2 (0.9) 2.9 (0.9) 0.001 
 
VAS-p 
1.2 (2)* 0.3 (1.2)* 0.002 
 
VAS-f 
















     1-OH (n (%)) 9 (18%) 13 (26%) 0.001 
     2-OH (n (%)) 13 (26%) 17 (34%) 0.05 
 
AIMS 
0.3 (1) 4 (7) < 0.001 
 
S&E 
35.8 (12)  30 (12) < 0.001 
 
HY 
4 (1) 3.8 (1) 0.0019 
L-dopa dose (mg) 336 (102) 
Ocurrence of AEs  
11 patients (22%) = drowsiness, 3 patients = 
symptomatic hypotension (6%), 2 patients 


























• Late-stage Parkinson’s disease patients have a high functional dependence; 
• After one year, one-fifth dies and the remaining become more disabled; 
• Dysphagia severity predicts a poor outcome (death, institutionalization, HY 5); 
• L-dopa responsiveness seems to have no impact on prog osis; 
• The management of dysphagia should be a priority of late disease stage.  
